Literature DB >> 28941473

New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis.

Jean-Claude Roujeau1, Maja Mockenhaupt2, Jean-Claude Guillaume3, Jean Revuz4.   

Abstract

Sixty years after its original description by Sir Alan Lyell, epidermal necrolysis (from Stevens-Johnson syndrome to toxic epidermal necrolysis) seems finally amenable to a specific treatment in addition to essential symptomatic measures in specialized settings. A recently published systematic review and an article by Gonzales-Herrada et al. strongly suggest that cyclosporine is effective in reducing the risk of death.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28941473     DOI： 10.1016/j.jid.2017.07.828

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


  9 in total

Review 1.  Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.

Authors:  S Shahzad Mustafa; David Ostrov; Daniel Yerly
Journal:  Curr Allergy Asthma Rep       Date:  2018-03-24       Impact factor: 4.806

2.  Lower-than-predicted mortality in a predominantly HIV-infected population with epidermal necrolysis regardless of HIV status: implications and challenges for interventional studies.

Authors:  Rannakoe J Lehloenya; Niita Haitembu; Wisdom Basera; Jonny Peter
Journal:  J Allergy Clin Immunol Pract       Date:  2018-11-15

Review 3.  SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

Authors:  Katie D White; Riichiro Abe; Michael Ardern-Jones; Thomas Beachkofsky; Charles Bouchard; Bruce Carleton; James Chodosh; Ricardo Cibotti; Robert Davis; Joshua C Denny; Roni P Dodiuk-Gad; Elizabeth N Ergen; Jennifer L Goldman; James H Holmes; Shuen-Iu Hung; Mario E Lacouture; Rannakoe J Lehloenya; Simon Mallal; Teri A Manolio; Robert G Micheletti; Caroline M Mitchell; Maja Mockenhaupt; David A Ostrov; Rebecca Pavlos; Munir Pirmohamed; Elena Pope; Alec Redwood; Misha Rosenbach; Michael D Rosenblum; Jean-Claude Roujeau; Arturo P Saavedra; Hajirah N Saeed; Jeffery P Struewing; Hirohiko Sueki; Chonlaphat Sukasem; Cynthia Sung; Jason A Trubiano; Jessica Weintraub; Lisa M Wheatley; Kristina B Williams; Brandon Worley; Wen-Hung Chung; Neil H Shear; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jan - Feb

Review 4.  Bullous Drug Reactions.

Authors:  Maja Mockenhaupt
Journal:  Acta Derm Venereol       Date:  2020-02-12       Impact factor: 3.875

Review 5.  Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Akito Hasegawa; Riichiro Abe
Journal:  F1000Res       Date:  2020-06-16

Review 6.  Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies.

Authors:  Yanping Li; Ruoqiu Fu; Tingting Jiang; Dongyu Duan; Yuanlin Wu; Chen Li; Ziwei Li; Rui Ni; Li Li; Yao Liu
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244

7.  Drug eruptions with novel targeted therapies - immune checkpoint and EGFR inhibitors.

Authors:  Isabella Pospischil; Wolfram Hoetzenecker
Journal:  J Dtsch Dermatol Ges       Date:  2021-11       Impact factor: 5.231

Review 8.  A contemporary snippet on clinical presentation and management of toxic epidermal necrolysis.

Authors:  Piyu Parth Naik
Journal:  Scars Burn Heal       Date:  2022-09-13

9.  Disease severity and status in Stevens-Johnson syndrome and toxic epidermal necrolysis: Key knowledge gaps and research needs.

Authors:  Rannakoe J Lehloenya
Journal:  Front Med (Lausanne)       Date:  2022-09-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.